SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Madrigal Pharmaceuticals Inc (MDGL)

MDGL RSS Feed
Add MDGL Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 11/14/2016 6:35:23 PM - Followers: 9 - Board type: Free - Posts Today: 0

 
WEBSITE: http://www.madrigalpharma.com


NEW MADRIGAL/SYNTA CORPORATE PRESENTATION:

http://www.madrigalpharma.com/wp-content/uploads/2016/05/Synta-Madrigal-Corporate-Slide-Deck-2060501.pdf
Madrigal Pharmaceuticals is developing novel, high-quality small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease and non-alcoholic steatohepatitis (NASH), diabetes, dyslipidemia and cardiovascular disease. Madrigal’s lead drug candidate is MGL-3196, a Phase 2 ready orally administered liver-directed thyroid hormone receptor-ß (THR-ß) agonist. In Madrigal’s 14-day multiple dose Phase 1 study in healthy volunteers with mildly elevated LDL cholesterol, MGL-3196 demonstrated safety and excellent tolerability at all doses tested. In the multiple dose study, MGL-3196 demonstrated proof-of-concept for lipid lowering including dose-dependent, highly significant, up to 30% lowering of LDL cholesterol and non-HDL cholesterol, and a strong trend of up to 60% triglyceride lowering. These results suggest that MGL-3196 has a unique lipid lowering profile as compared with other agents and a potential to significantly reduce cholesterol, triglycerides and liver triglycerides. Elevated cholesterol, triglycerides and fatty liver are an underlying cause of many metabolic and cardiovascular diseases, which, themselves, are associated with increased mortality.

In addition, MGL-3196 is a NASH target supported by compelling human biology and genetics. NASH is a serious liver disease found in individuals with fatty liver disease that is associated with hypothyroidism, diabetes, obesity, and dyslipidemia. MGL-3196 Phase 1 human data demonstrate safety and benefit in NASH-related dyslipidemia, and data from MGL-3196 treated NASH animal models support efficacy in NASH at doses relevant to humans.
 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MDGL
Current Price
Volume:
Bid Ask Day's Range
SureTrader
MDGL News: Statement of Changes in Beneficial Ownership (4) 11/21/2016 04:42:53 PM
MDGL News: Initial Statement of Beneficial Ownership (3) 11/21/2016 04:42:01 PM
MDGL News: Amended Quarterly Report (10-q/a) 11/16/2016 05:01:48 PM
MDGL News: Current Report Filing (8-k) 11/14/2016 05:07:56 PM
MDGL News: Madrigal Reports Third Quarter 2016 Financial Results 11/14/2016 04:30:00 PM
PostSubject
#12   MDGL had $39.6M cash at 9/30/16: #msg-126548759. DewDiligence 11/14/16 06:35:23 PM
#11   Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License djpope 09/19/16 10:20:34 AM
#10   Going up finally! luckystar17 08/30/16 10:26:17 AM
#9   Any news? Did they split after the split? luckystar17 08/23/16 01:02:47 PM
#8   That is just nonsense. It will go down tob999 07/27/16 06:22:34 PM
#7   This will go down to penny land in Adgonca 07/27/16 06:16:25 PM
#6   Out. Scumbag MMs doing their corrupt thing post tob999 07/26/16 03:46:45 PM
#5   Madrigal Pharmaceuticals Completes Merger with Synta to Create tob999 07/26/16 09:23:48 AM
#4   $40M cash in the bank to advance its tob999 07/25/16 11:28:57 AM
#3   News out! tob999 07/25/16 11:25:29 AM
#2   New corporate presentation out today: tob999 07/25/16 11:02:52 AM
#1   MDGL..with its merger with Synta Pharmaceuticals this is tob999 07/25/16 11:01:36 AM
PostSubject